GLP-1 Medications Linked to Lower Breast Cancer Risk: New Study

Scientists have spent years searching for new methods to lower the risk of breast cancer. Now, researchers are focusing on a class of medications originally developed for Type 2 diabetes, which have more recently become widely known as weight-loss injections.

A large-scale observational study conducted by the University of Pennsylvania has examined the relationship between GLP-1 medications and breast cancer incidence, yielding surprising results.

A Massive Data Analysis of Over 111,000 Women

The University of Pennsylvania study utilized electronic health records to track breast cancer diagnoses among a significant cohort. The researchers analyzed data from more than 111,000 women between the ages of 45 and 80 who were classified as overweight or obese, meaning they had a Body Mass Index (BMI) of at least 25.

View this post on Instagram about University of Pennsylvania, Body Mass Index

From Instagram — related to University of Pennsylvania, Body Mass Index

These participants, who had an average age of 61, underwent breast examinations between 2022 and 2025. Of the total group, 15,264 women had been prescribed a GLP-1 medication prior to their examination, while 96,382 women had no documented treatment with these drugs.

To ensure a fair comparison, researchers created two highly similar groups. This matched analysis involved 30,528 women and accounted for variables such as age, weight, breast density, ethnicity, and the presence of Type 2 diabetes.

Did You Know? The study specifically focused on women with a BMI of 25 or higher. In medical terms, a BMI between 25 and 29.9 is classified as overweight, while a BMI of 30 or higher is categorized as obesity.

Lower Incidence Linked to GLP-1 Treatment

During the study period, breast cancer was diagnosed in 2,628 of the 111,646 women, which represents approximately two out of every 100 participants.

Lower Breast Cancer Risk Black and White

The data revealed a notable difference between the two groups: nearly 2 out of 100 women in the GLP-1 treatment group were diagnosed with breast cancer, compared to approximately 2.5 out of 100 women in the group not taking the medication.

This correlation remained consistent even after the researchers adjusted for age, breast density, and diabetes. The trend was observed across both Black and White women, as well as among those with and without Type 2 diabetes.

Expert Insight: Samantha Carter notes that the sheer scale of this study—incorporating over 111,000 women—provides a powerful starting point for research. However, the critical distinction here is between correlation and causation; while the numbers are promising, they do not yet prove the drug is the direct cause of the lower cancer rate.

Beyond Weight Loss: Potential Biological Mechanisms

Because obesity is a known risk factor for breast cancer, researchers wanted to determine if the benefit was simply due to weight loss. Interestingly, the lower risk of breast cancer persisted even when weight loss was factored into the analysis.

Starting and stopping GLP‑1 meds may undermine results: Study

This suggests that GLP-1 medications may offer protective effects that are not solely dependent on a reduction in body weight. Researchers point to laboratory and animal studies suggesting these drugs could directly influence biological processes involved in cancer development.

Potential mechanisms being discussed include anti-inflammatory effects and changes to the metabolic processes within cancer cells, though these have not yet been proven in humans.

Crucial Limitations and Next Steps

Despite the findings, the researchers emphasize that this was an observational study. This means it cannot prove a direct cause-and-effect relationship between the medication and the lower incidence of cancer.

The study also had several gaps: it did not track the specific dosage of the medication, the length of time the women had been taking the drugs, or which specific GLP-1 agent was used.

these results should not be used to recommend GLP-1 medications for the prevention of breast cancer. The authors state that randomized clinical trials—where participants are randomly assigned to treatment groups—are the only way to determine if these drugs truly reduce cancer risk.

Frequently Asked Questions

Can GLP-1 medications now be recommended to prevent breast cancer?
No. The study shows a correlation, but it does not prove that the medications cause a reduction in cancer. Clinical trials are needed before any such recommendation can be made.

Is the potential protective effect only for women with diabetes?
No. The study found that the lower incidence of breast cancer was present in women both with and without Type 2 diabetes.

Is the lower risk just a result of losing weight?
The data suggests otherwise. The lower risk remained even when researchers accounted for weight loss, indicating a possible biological effect beyond just weight reduction.

Do you think weight-loss medications will eventually be repurposed for cancer prevention?